Lanreotide acetate

About the Target

Lanreotide (Laromustine, Angiopeptin, BIM 23014, Dermopeptin, Ipstyl, ITM-014, Somatulina, Somatuline, Lanreotidum) acetate, an analog of the native somatostatin peptide, is a physiological inhibitor of growth hormone (GH). The mapped target for this entry is Somatostatin receptor 2; Somatostatin receptor 5 (SSTR2 and SSTR5). This target context is most often investigated as part of ligand-responsive signaling, where receptor occupancy can reshape downstream second-messenger output, trafficking, secretion, excitability, or transcriptional programs. Researchers often examine this biology in oncology-focused models, where altered pathway tone can influence proliferation, stress adaptation, invasive behavior, and survival. This framing is especially useful when investigators want to connect a controlled ligand stimulus with rapidly changing cellular phenotypes.

Research Context

As an agonist-format peptide, it is typically used to trigger pathway activation on demand and to compare acute signaling events with longer adaptive changes such as receptor desensitization or altered transcriptional output. In practice, dose-response design, timing, and matched control conditions are important for separating direct target engagement from delayed compensatory responses. Because more than one mapped molecular node is represented in the enrichment, pathway readouts should be interpreted with awareness that the phenotype may integrate multiple signaling inputs.

• pair peptide treatment with pathway-proximal signaling or trafficking readouts whenever possible
• compare responses across cell states or model systems with different receptor abundance
• distinguish primary target engagement from downstream adaptation during longer incubations

Experimental interpretation should therefore connect early pathway changes with later phenotypic outputs, rather than relying on a single endpoint in isolation.

Format Considerations

Using the regular format helps keep comparative experiments aligned, especially when the same signaling question is being tested across multiple models or readout platforms. In comparative workflows, keeping the listed acetate format constant across comparator groups can reduce avoidable formulation-related differences. This is particularly helpful for comparative experiments, benchmark studies, and orthogonal validation in which small differences in formulation or handling can complicate interpretation. For peptide-centered workflows, conclusions are usually strongest when biological readouts are paired with consistent preparation and appropriately matched reference conditions.